The Cognite Atlas AI™ Definitive Guide to Industrial Agents Launched as the Premiere AI Manual for Industry
5.9.2024 15:00:00 CEST | Business Wire | Press release
The book is a must-read for transformation leaders looking to accelerate AI innovation and reduce time to value of their digital transformation programs
Cognite, the globally recognized authority in AI for industry, today announcedthe launch ofThe Cognite Atlas AI™Definitive Guide to Industrial Agents, a comprehensive manual for companies looking to accelerate the development and scale of AI solutions and reduce time to value.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240904796303/en/
The Cognite Atlas AI™ Definitive Guide to Industrial Agents Launched as the Premiere AI Manual for Industry. (Photo: Business Wire)
The book explores advancements in AI over the past year and expands on industrial AI agents and the latest technological requirements necessary to make AI work for industry. The Cognite Atlas AI™ Definitive Guide to Industrial Agents offers real-world examples, practical advice, and tools digital leaders can use to implement AI agents that can improve decision-making processes and help their organizations achieve higher productivity, safety, and overall operational efficiency.
“According to a recent ARC Advisory Group Digital Transformation, Sustainability, and Technology survey, AI is the most impactful technology we'll see over the next five years,” said Janice Abel, ARC Advisory Group Principal Technology Analyst. “The Cognite Atlas AI™ Definitive Guide to Industrial Agents is a practical place to start for digital leaders looking to make AI work in complex industrial environments.”
“Cognite Atlas AI enables us to use AI to enhance decision-making and improve efficiency, like with an industrial agent fine-tuned to understand unstructured technical documentation and Aker BP’s equipment hierarchy," said Paula Doyle, Chief Digital Officer at Aker BP. "By implementing the Document Parser AI Agent, we are streamlining our equipment management process, saving thousands of hours of data-punching, and refocusing our experts on business problems that really matter to the short- and long-term success of our operation.”
“Data lakes and copilots are just the beginning. Industrial AI demands more than a one-size-fits-all approach,” said Paul Grenet, Chief Revenue Officer at Cognite. “Cognite Atlas AI unlocks the full potential of generative AI for industry with industrial agents that can accelerate efficiencies and generate tens of millions of dollars in business impact. These agents enable a new wave of intelligent, domain-specific applications that revolutionize how industries operate."
The Cognite Atlas AI™ Definitive Guide to Industrial Agents is the third installment of the Cognite Definitive Guide series, which also includes The Definitive Guide to Generative AI for Industryand The Definitive Guide to Industrial DataOps. The series demystifies industrial digitalization and helps make sense of the journey industrial companies must take to evaluate, adopt, and scale AI solutions across their organizations.
The full digital version of the book is available online for free. Physical copies are available by request. Visit Cognite.ai to learn more.
About Cognite
Cognite makes Generative AI work for industry. Leading energy, manufacturing, and power & renewables enterprises choose Cognite to deliver secure, trustworthy, and real-time data to transform their asset-heavy operations to be safer, more sustainable, and more profitable. Cognite provides a user-friendly, secure, and scalable platform that makes it easy for all decision-makers, from the field to remote operations centers, to access and understand complex industrial data, collaborate in real-time, and build a better tomorrow. Visit us at www.cognite.ai and follow us on LinkedIn and Twitter.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240904796303/en/
Contacts
Michelle Holford
Michelle Holford
Vice President, Global PR, Cognite
Michelle.holford@cognite.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom